Reaction

Enterovirus Infection reporting signals

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 844 reports · 43 co-occurring drugs

As of the last recalculation, Enterovirus Infection appears in 844 FAERS reports alongside 43 co-occurring drug terms. The strongest observed disproportionality signal is MERCAPTOPURINE (PRR 70.7).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.

Drug	Co-reports	PRR	ROR
Mercaptopurine	47	70.7	70.9
Valganciclovir Hydrochloride Powder,	29	60.7	60.8
Palivizumab	33	55.1	55.2
Valganciclovir	35	47.7	47.8
Valganciclovir Hydrochloride	35	47.7	47.8
Pegaspargase	20	41.2	41.3
Vigabatrin	23	40.0	40.0
Basiliximab	18	38.5	38.6
Abacavir Sulfate	14	36.0	36.1
Vincristine Sulfate	37	32.5	32.6
Micafungin Sodium	10	29.4	29.5
Mycophenilic Acid	24	29.4	29.4
Tacrolimus Ointment 0.1%	125	28.9	28.9
Tacrolimus Extended-Release Capsules	125	28.8	28.8
Dolutegravir Sodium	10	27.7	27.7
Sirolimus	14	26.0	26.1
Trimethoprim	12	25.5	25.5
Cytarabine	57	25.0	25.0
Fludarabine Phosphate	38	24.9	24.9
Tacrolimus	128	23.6	23.6
Melphalan	20	22.2	22.2
Clobazam	20	20.7	20.7
Melphalan Hydrochloride	20	20.1	20.1
Obinutuzumab	13	19.8	19.8
Dornase Alfa	15	19.2	19.2
Mycophenolic Acid	24	19.0	19.0
Thiotepa	7	18.2	18.2
Doxorubicin Hydrochloride	21	16.2	16.2
Acalabrutinib	7	14.4	14.4
Cyclophosphamide Injection, Solution	89	13.7	13.7
Cyclophosphamide	89	13.7	13.7
Cyclophosphamide For Injection	89	13.7	13.7
Rifampin	8	13.6	13.6
Doxorubicin	46	13.4	13.4
Ruxolitinib	37	13.3	13.3
Tobramycin	12	12.5	12.5
Cannabidiol	11	11.7	11.7
Lumacaftor And Ivacaftor	4	11.6	11.6
Bosentan	21	10.5	10.5
Bendamustine Hydrochloride	5	10.4	10.4
Azacitidine For	7	9.6	9.6
Canakinumab	4	9.2	9.2
Elexacaftor, Tezacaftor, And Ivacaftor	3	5.9	6.0

Related reactions

Data source: openFDA FAERS. See the OpenPV methodology and limitations.